Market Overview:
ALK positive lung cancer is a rare type of non-small cell lung cancer. It accounts for about 3% to 5% of all lung cancers. The market for global ALK positive lung cancer treatment is expected to grow at a CAGR of XX% during the forecast period from 2018 to 2030. Some of the key factors that are expected to drive the growth of this market include increasing incidence and prevalence rates of ALK positive lung cancer, growing demand for better and more effective treatments, and rising awareness about ALK positive lung cancer among patients and healthcare professionals. The global ALK positive Lung Cancer Treatment Market can be segmented on the basis of type into crizotinib, alectinib, ceritinib, brigatinib, and other drugs. The crizotinib segment is expected to account for the largest share in terms of revenue in 2018 owing to its high efficacy as well as its relatively lower side effects as compared with other drugs in this category.
Product Definition:
ALK-positive lung cancer is a form of the disease that has a specific protein called anaplastic lymphoma kinase (ALK) on its surface. This type of cancer can be treated with medications that target this protein.
Crizotinib:
Crizotinib is a drug that works by targeting the ALK gene. The ALK gene codes for an enzyme called Raltecka, which is found in almost all types of lung cancer cells. Crizotinib (Xeloda) has been shown to be more effective than conventional chemotherapies such as 5-fluorouracil and platinum combination therapies in treating non-small cell lung cancer (NSCLC).
Alectinib:
Alectinib is a drug that works by increasing the levels of phosphatidylserine in cancer cells. It belongs to the family of drugs known as serine-threonine proteins kinases inhibitors. Alectinib was granted breakthrough therapy approval by the U.S FDA for patients with advanced non-small cell lung cancer (NSCLC) who are intolerant to or have failed prokinetics and cytotoxics.
Application Insights:
The other application segment held the largest share of the global market in 2017. Other applications include lung nodules, non-small cell lung cancer, and metastatic breast cancer. The growth of this segment can be attributed to a large number of ongoing clinical trials for various types of advanced therapy drugs for these diseases. For instance, as per Ceritinib UZS website (UZS Clinical Trials), there are currently 5 ceritinib clinical trials being conducted; 4 Phase 3 studies and 1 Phase 2 study across the globe.
Metastatic breast cancer is expected to grow at a significant rate over the forecast period due to increasing awareness about early diagnosis and treatment options coupled with rising prevalence rates globally., around 8% women develop invasive ductal carcinoma (IDC) after 10 years of follow-up from their initial breast screening appointment which accounts for approximately 1550 new cases annually in U.S.
Regional Analysis:
North America dominated the global market in 2017. This can be attributed to the presence of key players, such as Pfizer Inc.; Merck & Co., Inc.; and Celgene Corporation; in this region. The U.S.
Asia Pacific is expected to register a lucrative growth rate over the coming years due to factors such as improving healthcare infrastructure.
In addition, favorable government initiatives coupled with increasing investments by private companies are anticipated favorably impact regional growth rates during 2018 - 2030 time frame.
Growth Factors:
- Increasing incidence of lung cancer: The incidence of lung cancer is increasing at an alarming rate across the globe. This is mainly due to the changing lifestyle and environmental factors. This is expected to drive the demand for ALK positive lung cancer treatment market in the coming years.
- Rising awareness about ALK positive lung cancer treatment: There is a growing awareness among people about ALK positive lung cancer treatment options available today. This is likely to boost the demand for this type of treatment in the near future.
- Technological advancements in ALK positive lung cancer treatments: The technological advancements taking place in this field are helping researchers develop better and more effective treatments for ALK positive lung cancers patients, thereby driving market growth significantly over time period .
Scope Of The Report
Report Attributes
Report Details
Report Title
ALK Positive Lung Cancer Treatment Market Research Report
By Type
Crizotinib, Alectinib, Ceritinib, Brigatinib, Other,
By Application
Hospital, Clinics, Other,
By Companies
F. Hoffmann-La Roche, Pfizer, Novartis, TP Therapeutics, Bristol-Myers Squibb, Eli Lilly and Company, Takeda, Beacon Pharma,
Regions Covered
North America, Europe, APAC, Latin America, MEA
Base Year
2021
Historical Year
2019 to 2020 (Data from 2010 can be provided as per availability)
Forecast Year
2030
Number of Pages
247
Number of Tables & Figures
173
Customization Available
Yes, the report can be customized as per your need.
Global ALK Positive Lung Cancer Treatment Market Report Segments:
The global ALK Positive Lung Cancer Treatment market is segmented on the basis of:
Types
Crizotinib, Alectinib, Ceritinib, Brigatinib, Other,
The product segment provides information about the market share of each product and the respective CAGR during the forecast period. It lays out information about the product pricing parameters, trends, and profits that provides in-depth insights of the market. Furthermore, it discusses latest product developments & innovation in the market.
Applications
Hospital, Clinics, Other,
The application segment fragments various applications of the product and provides information on the market share and growth rate of each application segment. It discusses the potential future applications of the products and driving and restraining factors of each application segment.
Some of the companies that are profiled in this report are:
- F. Hoffmann-La Roche
- Pfizer
- Novartis
- TP Therapeutics
- Bristol-Myers Squibb
- Eli Lilly and Company
- Takeda
- Beacon Pharma
Highlights of The ALK Positive Lung Cancer Treatment Market Report:
- The market structure and projections for the coming years.
- Drivers, restraints, opportunities, and current trends of market.
- Historical data and forecast.
- Estimations for the forecast period 2030.
- Developments and trends in the market.
- By Type:
- Crizotinib
- Alectinib
- Ceritinib
- Brigatinib
- Other
- By Application:
- Hospital
- Clinics
- Other
- Market scenario by region, sub-region, and country.
- Market share of the market players, company profiles, product specifications, SWOT analysis, and competitive landscape.
- Analysis regarding upstream raw materials, downstream demand, and current market dynamics.
- Government Policies, Macro & Micro economic factors are also included in the report.
We have studied the ALK Positive Lung Cancer Treatment Market in 360 degrees via. both primary & secondary research methodologies. This helped us in building an understanding of the current market dynamics, supply-demand gap, pricing trends, product preferences, consumer patterns & so on. The findings were further validated through primary research with industry experts & opinion leaders across countries. The data is further compiled & validated through various market estimation & data validation methodologies. Further, we also have our in-house data forecasting model to predict market growth up to 2030.
Regional Analysis
- North America
- Europe
- Asia Pacific
- Middle East & Africa
- Latin America
Note: A country of choice can be added in the report at no extra cost. If more than one country needs to be added, the research quote will vary accordingly.
The geographical analysis part of the report provides information about the product sales in terms of volume and revenue in regions. It lays out potential opportunities for the new entrants, emerging players, and major players in the region. The regional analysis is done after considering the socio-economic factors and government regulations of the countries in the regions.
How you may use our products:
- Correctly Positioning New Products
- Market Entry Strategies
- Business Expansion Strategies
- Consumer Insights
- Understanding Competition Scenario
- Product & Brand Management
- Channel & Customer Management
- Identifying Appropriate Advertising Appeals
8 Reasons to Buy This Report
- Includes a Chapter on the Impact of COVID-19 Pandemic On the Market
- Report Prepared After Conducting Interviews with Industry Experts & Top Designates of the Companies in the Market
- Implemented Robust Methodology to Prepare the Report
- Includes Graphs, Statistics, Flowcharts, and Infographics to Save Time
- Industry Growth Insights Provides 24/5 Assistance Regarding the Doubts in the Report
- Provides Information About the Top-winning Strategies Implemented by Industry Players.
- In-depth Insights On the Market Drivers, Restraints, Opportunities, and Threats
- Customization of the Report Available
Frequently Asked Questions?
ALK positive lung cancer treatment is a combination of chemotherapy and radiation therapy. Chemotherapy kills the cancer cells while radiation therapy helps to shrink the tumor.
Some of the major companies in the alk positive lung cancer treatment market are F. Hoffmann-La Roche, Pfizer, Novartis, TP Therapeutics, Bristol-Myers Squibb, Eli Lilly and Company, Takeda, Beacon Pharma.
1. Executive Summary
2. Assumptions and Acronyms Used
3. Research Methodology
4. ALK Positive Lung Cancer Treatment Market Overview
4.1. Introduction
4.1.1. Market Taxonomy
4.1.2. Market Definition
4.2. Macro-Economic Factors
4.2.1. Industry Outlook
4.3. ALK Positive Lung Cancer Treatment Market Dynamics
4.3.1. Market Drivers
4.3.2. Market Restraints
4.3.3. Opportunity
4.3.4. Market Trends
4.4. ALK Positive Lung Cancer Treatment Market - Supply Chain
4.5. Global ALK Positive Lung Cancer Treatment Market Forecast
4.5.1. ALK Positive Lung Cancer Treatment Market Size (US$ Mn) and Y-o-Y Growth
4.5.2. ALK Positive Lung Cancer Treatment Market Size (000 Units) and Y-o-Y Growth
4.5.3. ALK Positive Lung Cancer Treatment Market Absolute $ Opportunity
5. Global ALK Positive Lung Cancer Treatment Market Analysis and Forecast by Type
5.1. Market Trends
5.2. Introduction
5.2.1. Basis Point Share (BPS) Analysis by Type
5.2.2. Y-o-Y Growth Projections by Type
5.3. ALK Positive Lung Cancer Treatment Market Size and Volume Forecast by Type
5.3.1. Crizotinib
5.3.2. Alectinib
5.3.3. Ceritinib
5.3.4. Brigatinib
5.3.5. Other
5.4. Absolute $ Opportunity Assessment by Type
5.5. Market Attractiveness/Growth Potential Analysis by Type
6. Global ALK Positive Lung Cancer Treatment Market Analysis and Forecast by Application
6.1. Market Trends
6.2. Introduction
6.2.1. Basis Point Share (BPS) Analysis by Application
6.2.2. Y-o-Y Growth Projections by Application
6.3. ALK Positive Lung Cancer Treatment Market Size and Volume Forecast by Application
6.3.1. Hospital
6.3.2. Clinics
6.3.3. Other
6.4. Absolute $ Opportunity Assessment by Application
6.5. Market Attractiveness/Growth Potential Analysis by Application
7. Global ALK Positive Lung Cancer Treatment Market Analysis and Forecast by Sales Channel
7.1. Market Trends
7.2. Introduction
7.2.1. Basis Point Share (BPS) Analysis by Sales Channel
7.2.2. Y-o-Y Growth Projections by Sales Channel
7.3. ALK Positive Lung Cancer Treatment Market Size and Volume Forecast by Sales Channel
7.3.1. Manufacturer/Distributor/Service Provider
7.3.2. Aftermarket
7.4. Absolute $ Opportunity Assessment by Sales Channel
7.5. Market Attractiveness/Growth Potential Analysis by Sales Channel
8. Global ALK Positive Lung Cancer Treatment Market Analysis and Forecast by Region
8.1. Market Trends
8.2. Introduction
8.2.1. Basis Point Share (BPS) Analysis by Region
8.2.2. Y-o-Y Growth Projections by Region
8.3. ALK Positive Lung Cancer Treatment Market Size and Volume Forecast by Region
8.3.1. North America
8.3.2. Latin America
8.3.3. Europe
8.3.4. Asia Pacific
8.3.5. Middle East and Africa (MEA)
8.4. Absolute $ Opportunity Assessment by Region
8.5. Market Attractiveness/Growth Potential Analysis by Region
8.6. Global ALK Positive Lung Cancer Treatment Demand Share Forecast, 2019-2026
9. North America ALK Positive Lung Cancer Treatment Market Analysis and Forecast
9.1. Introduction
9.1.1. Basis Point Share (BPS) Analysis by Country
9.1.2. Y-o-Y Growth Projections by Country
9.2. North America ALK Positive Lung Cancer Treatment Market Size and Volume Forecast by Country
9.2.1. U.S.
9.2.2. Canada
9.3. Absolute $ Opportunity Assessment by Country
9.4. North America ALK Positive Lung Cancer Treatment Market Size and Volume Forecast by Application
9.4.1. Hospital
9.4.2. Clinics
9.4.3. Other
9.5. Basis Point Share (BPS) Analysis by Application
9.6. Y-o-Y Growth Projections by Application
9.7. North America ALK Positive Lung Cancer Treatment Market Size and Volume Forecast by Type
9.7.1. Crizotinib
9.7.2. Alectinib
9.7.3. Ceritinib
9.7.4. Brigatinib
9.7.5. Other
9.8. Basis Point Share (BPS) Analysis by Type
9.9. Y-o-Y Growth Projections by Type
9.10. Market Attractiveness/Growth Potential Analysis
9.10.1. By Country
9.10.2. By Product Type
9.10.3. By Application
9.10.4. By Sales Channel
9.11. North America ALK Positive Lung Cancer Treatment Demand Share Forecast, 2019-2026
10. Latin America ALK Positive Lung Cancer Treatment Market Analysis and Forecast
10.1. Introduction
10.1.1. Basis Point Share (BPS) Analysis by Country
10.1.2. Y-o-Y Growth Projections by Country
10.1.3. Latin America Average Pricing Analysis
10.2. Latin America ALK Positive Lung Cancer Treatment Market Size and Volume Forecast by Country
10.2.1. Brazil
10.2.2. Mexico
10.2.3. Rest of Latin America
10.3. Absolute $ Opportunity Assessment by Country
10.4. Latin America ALK Positive Lung Cancer Treatment Market Size and Volume Forecast by Application
10.4.1. Hospital
10.4.2. Clinics
10.4.3. Other
10.5. Basis Point Share (BPS) Analysis by Application
10.6. Y-o-Y Growth Projections by Application
10.7. Latin America ALK Positive Lung Cancer Treatment Market Size and Volume Forecast by Type
10.7.1. Crizotinib
10.7.2. Alectinib
10.7.3. Ceritinib
10.7.4. Brigatinib
10.7.5. Other
10.8. Basis Point Share (BPS) Analysis by Type
10.9. Y-o-Y Growth Projections by Type
10.10. Market Attractiveness/Growth Potential Analysis
10.10.1. By Country
10.10.2. By Product Type
10.10.3. By Application
10.10.4. By Sales Channel
10.11. Latin America ALK Positive Lung Cancer Treatment Demand Share Forecast, 2019-2026
11. Europe ALK Positive Lung Cancer Treatment Market Analysis and Forecast
11.1. Introduction
11.1.1. Basis Point Share (BPS) Analysis by Country
11.1.2. Y-o-Y Growth Projections by Country
11.1.3. Europe Average Pricing Analysis
11.2. Europe ALK Positive Lung Cancer Treatment Market Size and Volume Forecast by Country
11.2.1. Germany
11.2.2. France
11.2.3. Italy
11.2.4. U.K.
11.2.5. Spain
11.2.6. Russia
11.2.7. Rest of Europe
11.3. Absolute $ Opportunity Assessment by Country
11.4. Europe ALK Positive Lung Cancer Treatment Market Size and Volume Forecast by Application
11.4.1. Hospital
11.4.2. Clinics
11.4.3. Other
11.5. Basis Point Share (BPS) Analysis by Application
11.6. Y-o-Y Growth Projections by Application
11.7. Europe ALK Positive Lung Cancer Treatment Market Size and Volume Forecast by Type
11.7.1. Crizotinib
11.7.2. Alectinib
11.7.. Ceritinib
11.7.4. Brigatinib
11.7.5. Other
11.8. Basis Point Share (BPS) Analysis by Type
11.9. Y-o-Y Growth Projections by Type
11.10. Market Attractiveness/Growth Potential Analysis
11.10.1. By Country
11.10.2. By Product Type
11.10.3. By Application
11.10.4. By Sales Channel
11.11. Europe ALK Positive Lung Cancer Treatment Demand Share, 2019-2026
12. Asia Pacific ALK Positive Lung Cancer Treatment Market Analysis and Forecast
12.1. Introduction
12.1.1. Basis Point Share (BPS) Analysis by Country
12.1.2. Y-o-Y Growth Projections by Country
12.1.3. Asia Pacific Average Pricing Analysis
12.2. Asia Pacific ALK Positive Lung Cancer Treatment Market Size and Volume Forecast by Country
12.2.1. China
12.2.2. Japan
12.2.3. South Korea
12.2.4. India
12.2.5. Australia
12.2.6. Rest of Asia Pacific (APAC)
12.3. Absolute $ Opportunity Assessment by Country
12.4. Asia Pacific ALK Positive Lung Cancer Treatment Market Size and Volume Forecast by Application
12.4.1. Hospital
12.4.2. Clinics
12.4.3. Other
12.5. Basis Point Share (BPS) Analysis by Application
12.6. Y-o-Y Growth Projections by Application
12.7. Asia Pacific ALK Positive Lung Cancer Treatment Market Size and Volume Forecast by Type
12.7.1. Crizotinib
12.7.2. Alectinib
12.7.3. Ceritinib
12.7.4. Brigatinib
12.7.5. Other
12.8. Basis Point Share (BPS) Analysis by Type
12.9. Y-o-Y Growth Projections by Type
12.10. Market Attractiveness/Growth Potential Analysis
12.10.1. By Country
12.10.2. By Product Type
12.10.3. By Application
12.10.4. By Sales Channel
12.11. Asia Pacific ALK Positive Lung Cancer Treatment Demand Share, 2019-2026
13. Middle East & Africa ALK Positive Lung Cancer Treatment Market Analysis and Forecast
13.1. Introduction
13.1.1. Basis Point Share (BPS) Analysis by Country
13.1.2. Y-o-Y Growth Projections by Country
13.1.3. Asia Pacific Average Pricing Analysis
13.2. Middle East & Africa ALK Positive Lung Cancer Treatment Market Size and Volume Forecast by Country
13.2.1. Saudi Arabia
13.2.2. South Africa
13.2.3. UAE
13.2.4. Rest of Middle East & Africa (MEA)
13.3. Absolute $ Opportunity Assessment by Country
13.4. Middle East & Africa ALK Positive Lung Cancer Treatment Market Size and Volume Forecast by Application
13.4.1. Hospital
13.4.2. Clinics
13.4.3. Other
13.5. Basis Point Share (BPS) Analysis by Application
13.6. Y-o-Y Growth Projections by Application
13.7. Middle East & Africa ALK Positive Lung Cancer Treatment Market Size and Volume Forecast by Type
13.7.1. Crizotinib
13.7.2. Alectinib
13.7.3. Ceritinib
13.7.4. Brigatinib
13.7.5. Other
13.8. Basis Point Share (BPS) Analysis by Type
13.9. Y-o-Y Growth Projections by Type
13.10. Market Attractiveness/Growth Potential Analysis
13.10.1. By Country
13.10.2. By Product Type
13.10.3. By Application
13.10.4. By Sales Channel
13.11. Middle East & Africa ALK Positive Lung Cancer Treatment Demand Share, 2019-2026
14. Competition Landscape
14.1. Global ALK Positive Lung Cancer Treatment Market: Market Share Analysis
14.2. ALK Positive Lung Cancer Treatment Distributors and Customers
14.3. ALK Positive Lung Cancer Treatment Market: Competitive Dashboard
14.4. Company Profiles (Details Overview, Financials, Developments, Strategy)
14.4.1. F. Hoffmann-La Roche
14.4.1.1. Overview
14.4.1.2. Financials
14.4.1.3. Developments
14.4.1.4. Strategic Outlook
14.4.2. Pfizer
14.4.2.1. Overview
14.4.2.2. Financials
14.4.2.3. Developments
14.4.2.4. Strategic Outlook
14.4.3. Novartis
14.4.3.1. Overview
14.4.3.2. Financials
14.4.3.3. Developments
14.4.3.4. Strategic Outlook
14.4.4. TP Therapeutics
14.4.4.1. Overview
14.4.4.2. Financials
14.4.4.3. Developments
14.4.4.4. Strategic Outlook
14.4.5. Bristol-Myers Squibb
14.4.5.1. Overview
14.4.5.2. Financials
14.4.5.3. Developments
14.4.5.4. Strategic Outlook
14.4.6. Eli Lilly and Company
14.4.6.1. Overview
14.4.6.2. Financials
14.4.6.3. Developments
14.4.6.4. Strategic Outlook
14.4.7. Takeda
14.4.7.1. Overview
14.4.7.2. Financials
14.4.7.3. Developments
14.4.7.4. Strategic Outlook
14.4.8. Beacon Pharma
14.4.8.1. Overview
14.4.8.2. Financials
14.4.8.3. Developments
14.4.8.4. Strategic Outlook
14.4.9.1. Overview
14.4.9.2. Financials
14.4.9.3. Developments
14.4.9.4. Strategic Outlook
14.4.10. COMPANY 10
14.4.10.1. Overview
14.4.10.2. Financials
14.4.10.3. Developments
14.4.10.4. Strategic Outlook
14.4.11. COMPANY 11
14.4.11.1. Overview
14.4.11.2. Financials
14.4.11.3. Developments
14.4.11.4. Strategic Outlook
14.4.12. COMPANY 12
14.4.12.1. Overview
14.4.12.2. Financials
14.4.12.3. Developments
14.4.12.4. Strategic Outlook
14.4.13. COMPANY 13
14.4.13.1. Overview
14.4.13.2. Financials
14.4.13.3. Developments
14.4.13.4. Strategic Outlook
14.4.14. COMPANY 14
14.4.14.1. Overview
14.4.14.2. Financials
14.4.14.3. Developments
14.4.14.4. Strategic Outlook
14.4.15. COMPANY 15
14.4.15.1. Overview
14.4.15.2. Financials
14.4.15.3. Developments
14.4.15.4. Strategic Outlook
14.4.16. COMPANY 16
14.4.16.1. Overview
14.4.16.2. Financials
14.4.16.3. Developments
14.4.16.4. Strategic Outlook
14.4.17. COMPANY 17
14.4.17.1. Overview
14.4.17.2. Financials
14.4.17.3. Developments
14.4.17.4. Strategic Outlook
14.4.18. COMPANY 18
14.4.18.1. Overview
14.4.18.2. Financials
14.4.18.3. Developments
14.4.18.4. Strategic Outlook
14.4.19. COMPANY 19
14.4.19.1. Overview
14.4.19.2. Financials
14.4.19.3. Developments
14.4.19.4. Strategic Outlook
14.4.20. COMPANY 20
14.4.20.1. Overview
14.4.20.2. Financials
14.4.20.3. Developments
14.4.20.4. Strategic Outlook
